Introduction

Cell and gene therapies have moved from experimental platforms to commercial reality. Hundreds of clinical programs are advancing worldwide, and manufacturing facilities are scaling rapidly to meet increasing demand. According to reports from the Alliance for Regenerative Medicine, investment and clinical activity in the cell and gene therapy sector continue to grow year after year, placing greater pressure on manufacturers to maintain product quality while increasing production capacity.

Among the many quality challenges facing advanced therapy manufacturers, endotoxin contamination remains one of the most significant.

Unlike microbial contamination, endotoxins cannot be eliminated simply by sterilization. They may persist after bacteria are destroyed and can trigger severe pyrogenic and inflammatory responses in patients even at extremely low concentrations.

For this reason, regulatory agencies require endotoxin testing as part of product release. However, modern GMP expectations extend far beyond final product testing. Manufacturers are increasingly expected to implement proactive contamination control strategies supported by risk assessment, process understanding, supplier qualification, and routine monitoring.

The most successful quality programs do not simply detect endotoxins. They identify contamination risks before they become product quality failures.

This guide explores practical approaches to endotoxin risk assessment and contamination control in cell and gene therapy manufacturing, including common contamination sources, critical control points, Low Endotoxin Recovery (LER), investigation strategies, and the role of TAL/LAL Reagent testing throughout the product lifecycle.

Why Endotoxin Contamination Matters in Cell and Gene Therapy Manufacturing

Endotoxins are lipopolysaccharides (LPS) derived from the outer membrane of Gram-negative bacteria.

When introduced into the human body, endotoxins may cause:

• Fever and pyrogenic reactions
• Excessive immune activation
• Inflammatory responses
• Product batch rejection
• Manufacturing deviations
• Regulatory observations
• Supply chain disruptions

Cell and gene therapy products are particularly sensitive because they frequently involve:

• Living cells
• Viral vectors
• Complex biological raw materials
• Multi-step manufacturing processes
• Extended processing timelines

Each additional material and process step introduces another opportunity for endotoxin contamination.

Importantly, a product can be sterile and still fail endotoxin testing.

This distinction is often overlooked outside specialized quality and microbiology teams.

From Endotoxin Testing to Endotoxin Risk Management

Historically, endotoxin control focused primarily on release testing.

Today, regulators increasingly expect manufacturers to implement risk-based contamination control strategies aligned with:

• ICH Q9 Quality Risk Management
• EU GMP Annex 1
• FDA Guidance for Industry
• USP <85>
• USP <86>

Endotoxin testing answers one question:

Is endotoxin detectable in this sample?

Endotoxin risk assessment answers a broader question:

Where can endotoxin contamination occur, and how can it be prevented before it affects product quality?

This shift from detection to prevention is one of the most important trends in modern pharmaceutical quality systems.

Regulatory Expectations in 2026

Current endotoxin control programs are typically built upon:

• USP <85> Bacterial Endotoxins Test
• USP <86> Bacterial Endotoxins Test Using Recombinant Reagents
• FDA Guidance for Pyrogen and Endotoxins Testing
• EU GMP Annex 1
• ICH Q9 Quality Risk Management

Although recombinant methods continue to gain attention following the publication of USP <86>, TAL/LAL Reagent-based methods remain the most widely implemented endotoxin testing technologies throughout the pharmaceutical industry.

Most commercial manufacturing facilities continue to rely on:

• Gel Clot TAL/LAL Reagent
• Kinetic Chromogenic TAL/LAL Reagent
• Kinetic Turbidimetric TAL/LAL Reagent

for routine endotoxin testing and process monitoring.

For a deeper discussion of regulatory trends and method selection considerations, see:

[USP <86> and FDA 2026 Guidance: Navigating the New Dual-Track Era of Endotoxin Testing]

The Most Common Sources of Endotoxin Contamination

Raw Materials

Raw materials consistently represent one of the highest-risk contamination categories.

Examples include:

• Cell culture media
• Cytokines
• Growth factors
• Plasmid DNA
• Buffers
• Process intermediates

Even well-qualified suppliers may experience variability between lots.

As a result, many manufacturers incorporate incoming material endotoxin testing into supplier qualification programs.

Risk Level: Critical

Water Systems

Water systems remain one of the most frequently cited sources of endotoxin contamination in pharmaceutical manufacturing.

Potential contributors include:

• Biofilm formation
• Inadequate sanitization
• Dead-leg piping
• Distribution loop contamination
• Maintenance deficiencies

Routine monitoring and trending are essential.

Risk Level: Critical

Single-Use Technologies

Single-use systems have transformed biologics manufacturing.

Industry surveys suggest that more than 70% of biologics facilities now incorporate single-use technologies in at least part of their operations.

Examples include:

• Disposable bioreactors
• Tubing assemblies
• Transfer bags
• Connectors
• Filters

Although these components are typically sterile, sterility does not necessarily indicate low endotoxin burden.

Risk Level: High

Viral Vector Manufacturing

AAV and lentiviral vector manufacturing involve numerous biological materials and processing steps.

Potential endotoxin sources include:

• Plasmid preparation
• Cell banks
• Transfection reagents
• Harvest operations
• Purification intermediates

Each stage introduces additional contamination opportunities.

Risk Level: High

Personnel and Process Interventions

Human intervention remains one of the most difficult contamination risks to control completely.

Examples include:

• Sampling activities
• Equipment setup
• Material transfers
• Aseptic interventions

Risk Level: Moderate

Endotoxin Risk Matrix for Cell and Gene Therapy Manufacturing

A practical way to prioritize contamination control activities is through risk ranking.

Potential Source	Likelihood	Severity	Overall Risk
Water Systems	High	High	Critical
Raw Materials	High	High	Critical
Viral Vector Production	Medium	High	High
Single-Use Assemblies	Medium	Medium	High
Personnel Intervention	Medium	Medium	Moderate
Environmental Sources	Low	Medium	Low

This type of risk matrix helps quality teams focus monitoring resources where they are most likely to reduce product risk.

Identifying Critical Control Points (CCPs)

Not all process steps require the same level of monitoring.

Examples of common CCPs include:

Incoming Raw Material Release

Early screening prevents contaminated materials from entering manufacturing.

Water-for-Injection Systems

Continuous monitoring is essential.

Viral Vector Harvest

Frequently identified as a high-risk manufacturing stage.

Final Formulation

Often represents the last opportunity to identify contamination before release.

Example Investigation Scenario

A commercial lentiviral vector manufacturing facility observed repeated elevated endotoxin results during release testing.

Initial review showed:

• Acceptable environmental monitoring
• No equipment failures
• No major process deviations
• Qualified suppliers

A structured endotoxin risk assessment ultimately identified a single-use transfer assembly introduced during upstream processing as the likely contamination source.

Corrective actions included:

• Enhanced incoming component testing
• Supplier requalification
• Additional in-process monitoring
• Updated risk assessment procedures

The investigation demonstrated a common reality of endotoxin control:

The source of contamination is often discovered far upstream from where contamination is ultimately detected.

Low Endotoxin Recovery (LER): The Hidden Challenge

One of the most important endotoxin-related developments of the last decade has been the recognition of Low Endotoxin Recovery (LER).

LER occurs when formulation components reduce the detectability of endotoxin.

Potential masking agents include:

• Surfactants
• Polysorbates
• Chelators
• Protein-rich formulations

Potential consequences include:

• False-negative results
• Underestimated contamination risk
• Product quality concerns
• Regulatory scrutiny

LER evaluation should be incorporated into every modern endotoxin risk assessment program.

For a detailed discussion of endotoxin masking mechanisms, see:

[Low Endotoxin Recovery (LER): Causes, Endotoxin Masking Mechanisms, Regulatory Expectations, and Practical Solutions]

How USP <86 Influences Method Selection

USP <86> has expanded the range of available endotoxin testing approaches.

When selecting an endotoxin testing method, manufacturers should consider:

• Product matrix complexity
• Method suitability data
• Potential LER concerns
• Regulatory expectations
• Validation requirements

Rather than viewing USP <85> and USP <86> as competing standards, many organizations treat them as complementary tools within a broader contamination control strategy.

Why Kinetic Chromogenic TAL/LAL Reagent Testing Is Growing

Many QC laboratories increasingly favor kinetic chromogenic TAL/LAL Reagent assays because they provide:

• Quantitative results
• Broad dynamic range
• High throughput
• Automated analysis
• Improved trend monitoring

These characteristics make kinetic chromogenic assays particularly valuable for contamination control programs focused on long-term risk management.

For more information:

[Why Kinetic Chromogenic Endotoxin Testing Is Becoming Essential for Cell and Gene Therapy Manufacturing in 2026]

What To Do When Endotoxin Testing Fails

An unexpected endotoxin result should never be treated as an isolated laboratory event.

A structured investigation typically includes:

Step 1: Confirm the Result

Review:

• Positive controls
• Negative controls
• Standard curve performance
• Analyst observations

Step 2: Assess Laboratory Factors

Evaluate:

• Pipetting accuracy
• Reagent integrity
• Instrument performance
• Sample preparation procedures

Step 3: Investigate Manufacturing Inputs

Review:

• Water systems
• Raw materials
• Supplier changes
• Single-use components

Step 4: Evaluate Process Deviations

Assess:

• Unexpected interventions
• Equipment maintenance
• Environmental excursions

Step 5: Assess Potential LER

Determine whether endotoxin masking could have affected previous results.

Step 6: Implement CAPA

Corrective and preventive actions should be documented, implemented, and verified through ongoing monitoring.

Building a Comprehensive Endotoxin Control Program

Effective contamination control requires four integrated pillars.

Prevention

• Supplier qualification
• Water system control
• Process design

Detection

• TAL/LAL Reagent testing
• Environmental monitoring
• In-process testing

Investigation

• Root cause analysis
• Trending review
• Deviation management

Continuous Improvement

• Risk assessment updates
• Method suitability reviews
• LER evaluations
• CAPA effectiveness monitoring

Key Takeaways

• Endotoxin testing alone is not sufficient for modern cell and gene therapy manufacturing.
• Raw materials and water systems remain the most common sources of endotoxin contamination.
• Effective risk assessment begins during process design, not product release.
• Low Endotoxin Recovery (LER) should be evaluated proactively.
• USP <86> expands available testing options but does not eliminate the importance of established TAL/LAL Reagent methods.
• Successful contamination control programs integrate prevention, detection, investigation, and continuous improvement.

Frequently Asked Questions

What is endotoxin risk assessment?

A systematic process used to identify, evaluate, and control endotoxin contamination risks throughout manufacturing.

What is the difference between endotoxin testing and endotoxin risk assessment?

Testing detects contamination, while risk assessment focuses on preventing contamination.

Can sterile products contain endotoxin?

Yes. Sterility does not guarantee the absence of endotoxins.

What are the most common endotoxin contamination sources?

Raw materials, water systems, viral vector manufacturing processes, and single-use technologies.

Can endotoxin pass through sterile filters?

Yes. Endotoxins may remain present even when microorganisms have been removed.

What is endotoxin masking?

A phenomenon in which formulation components reduce endotoxin detectability.

What is method suitability testing?

A study demonstrating that a product matrix does not interfere with endotoxin detection.

What is the difference between USP <85> and USP <86>?

USP <85> covers traditional bacterial endotoxins testing methods, while USP <86> addresses recombinant reagent approaches.

Are recombinant endotoxin tests accepted by regulators?

Acceptance depends on validation data, method suitability, and regional requirements.

Why do endotoxin results vary between lots?

Variability may result from raw materials, manufacturing processes, environmental factors, or product matrix effects.

What is the endotoxin limit for cell therapy products?

Limits depend on product type, route of administration, and applicable regulatory guidance.

How do you investigate an endotoxin failure?

Through structured review of laboratory controls, manufacturing inputs, process deviations, water systems, and CAPA implementation.

Conclusion

As cell and gene therapy manufacturing continues to mature, endotoxin control strategies must evolve beyond simple release testing.

The organizations that consistently achieve successful inspections, reliable product quality, and efficient manufacturing operations are those that view endotoxin control as a lifecycle activity rather than a single analytical test.

By combining risk assessment, contamination control, supplier management, LER evaluation, and robust TAL/LAL Reagent testing programs, manufacturers can identify contamination risks early, reduce deviations, and improve overall product quality.

In the future of advanced therapies, the most effective endotoxin strategy will not be better detection alone—it will be preventing endotoxin contamination before it happens.